Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HB0017 injection in adults with active ankylosing spondylitis
CTR20251960Phase 3Active
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HB0017 in ankylosing spondylitis (AS) (3 arms), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoint: Proportion of subjects achieving ASAS 40 response. Started May 2025; status: active.
02
Drugs
HB0017
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20251960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251960.